December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artelo Biosciences, Inc. - Common Stock (NQ:ARTL)

4.080 -0.430 (-9.53%)
Streaming Delayed Price Updated: 1:23 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Artelo Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Nasdaq Falls Over 100 Points; Capgemini To Acquire WNS
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Recap: Artelo Biosciences Q4 Earnings
 
Via Benzinga
Recap: Artelo Biosciences Q3 Earnings
 
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Get insights into the top gainers and losers of Tuesday's pre-market session.
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Synergy CHC Corp. (NASDAQ: SNYR) Secures Distribution Wins for FOCUSfactor® Supplements and Functional Beverages – More Stocks Inside
Via AB Newswire
These stocks are moving in today's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial
The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter... 
Via Stocktwits
Crude Oil Moves Lower; Joby Aviation Shares Surge
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dow Gains Over 100 Points; Chicago PMI Weakens In June
 
Via Benzinga
Topics Stocks
Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday?
Artelo reports favorable Phase 1 results for its FABP5 inhibitor, showing strong safety data and dose-dependent absorption in 49 healthy participants. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
This UnitedHealth Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models
Artelo Biosciences advances ART26.12 for psoriasis and CIPN, while ART27.13 shows early promise in cancer-related anorexia studies. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program
Artelo Biosciences advances its pipeline with ART26.12 for neuropathic pain and ART27.13 for cancer-related anorexia, targeting 2025 milestones. 
Via Benzinga
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023
ARTL stock results show that Artelo Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.